Improved beta cell function after short-term treatment with XXXX in obese subjects with type 2 @entity6 .

@entity1 @entity6 @entity6335 @entity2690 @entity369 @entity413
OBJECTIVE: Our aim was to distinguish beneficial effects of B-cell rest from other effects of correction of hyperglycaemia. For this purpose we used @entity6335 which reversibly blocks @entity2690 secretion. MATERIAL AND METHODS: Eight obese (age 53 +/- 1 yr: BMI 33 +/- 2 kg/m2: 4 females) type 2 @entity6 @entity1 with poor metabolic control (HbA1c 8.7 +/- 0.9% ref.<5.2%) were studied twice after a randomly ordered treatment period of five days of intensive i.v. @entity2690 treatment alone or i.v. @entity2690 with peroral @entity6335 (300 mg/day, divided into 3 doses). The glycaemic control was not altered between the two treatment periods. @entity2690 secretion was measured in response to i.v. @entity413 and @entity369 . RESULTS: @entity2690 infusion was used to achieve close to identical degrees of glycaemia during the two treatment periods. Previous treatment with @entity6335 was associated with a moderate 1.9 +/- 0.6 fold rise in @entity2690 response to intravenous @entity413 (p=0.04) and 1.6 +/- 0.4 fold increased @entity413 potentiation of @entity369 -induced @entity2690 secretion (GPAIS) (p=0.04). Conversely, after @entity2690 alone there was no response to i.v. @entity413 and no change in GPAIS. CONCLUSIONS: Short-term @entity6335 treatment improved important parameters of B-cell function and these effects could be dissociated from confounding effects of changes in glycaemia. Consequently, the results indicate beneficial effects of B-cell rest.
